COLUMBIA ASIA HOSPITAL BUKIT JALIL LAUNCHES NEW CATH LAB TO STRENGTHEN HEART CARE SERVICES
The new cardiac catheterisation facility enables faster, minimally invasive treatment and improved access to specialist care, closer to home. KUALA LUMPUR, Malaysia, March 2, 2026 /PRNewswire/ -- Columbia Asia Hospital Bukit Jalil has officially launched its new Cardiac Catheterisation Laboratory (Cath Lab), marking a significant step forward in expanding access to advanced...
WuXi Biologics Included in S&P Global Sustainability Yearbook for Fourth Consecutive Year
SHANGHAI, March 2, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been included in the S&P Global Sustainability Yearbook 2026 ("Yearbook") in recognition of its strong performance in the 2025 Corporate Sustainability Assessment (CSA). The company was ranked top in its industry and achieved a Top 1% S&P...
XPOVIO® Receives Reimbursement Approval in South Korea for a Second Multiple Myeloma Indication
- XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health Insurance Service (NHIS) for the treatment of adult patients with multiple myeloma (MM). - In South Korea, XPOVIO® has been approved for three indications across MM and diffuse large B-cell lymphoma (DLBCL), and two of these approved...
Jaypirca® (Pirtobrutinib) Approved in China for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
SAN FRANCISCO and SUZHOU, China, March 2, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announces the non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, Jaypirca® (pirtobrutinib), has received approval by the National Medical...
Lynk Pharmaceuticals Announces Positive Phase III Topline Data of Zemprocitinib in Moderate-to-Severe Atopic Dermatitis
SHANGHAI, HANGZHOU, China and BOSTON, March 2, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on therapies for immune and inflammatory diseases, today announced positive topline results from its Phase III clinical trial evaluating zemprocitinib in patients with moderate-to-severe atopic dermatitis (AD). The study met all co-primary and key secondary...
Investor Education Webinar
The Future of Prostate Imaging: What do physicians want? MELBOURNE, Australia and INDIANAPOLIS, March 2, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") invites investors to join a webinar with key opinion leaders to discuss a physician's perspective on innovations in PSMA-PET/CT imaging for prostate cancer. Speakers: Rodney...
Nearly 4,000 Participants Join “On Track to Save 2026” as Revived Orienteering Competition Draws Over 100 Family Teams
HONG KONG, March 1, 2026 /PRNewswire/ -- Médecins Sans Frontières (MSF) Hong Kong successfully held its large‑scale running and orienteering competition, "On Track to Save 2026", today at the Hong Kong Science Park. The event saw its highest participation in recent years, with nearly 4,000 participants taking part in supporting medical humanitarian work. The well-loved orienteering competition also returned...
Dimora Medical Supports NPIAP 2026 Annual Conference as Exclusive Opening Ceremony Sponsor
NEW YORK, Feb. 28, 2026 /PRNewswire/ -- From February 26 to 27, the NPIAP 2026 Annual Conference was held in the United States, bringing together leading clinicians, researchers, and healthcare professionals to advance the prevention and management of pressure injuries. Dimora Medical, a continuous innovator in high-end medical care supplies, participated as the exclusive sponsor of the conference opening ceremony,...
BestQool’s BQ60Pro: Next-Generation 6-Wavelength Home Red Light Therapy Device with Enhanced Output and Smarter Flexibility
NEW YORK, Feb. 28, 2026 /PRNewswire/ -- Since the launch of BestQool, this company has always aimed to deliver the most for its customers and continuously improve its home-use products, focusing on red light therapy devices. BestQool's executives carefully summarized feedback on the BQ60 and developed an improved version, the BQ60Pro. Powered by an advanced 6-wavelength configuration, the...
Vatech Reports Industry-Leading 20-Year Patent Portfolio in Dental Diagnostic Imaging
Patent leadership reinforces company's leading position in the global CBCT market HWASEONG, South Korea, Feb. 27, 2026 /PRNewswire/ -- Vatech (KOSDAQ: 043150), a global manufacturer of dental imaging systems, announced that cumulative patent data over the past 20 years demonstrate its technological leadership in dental diagnostic imaging. Under the internationally recognized IPC classification...
